-+ 0.00%
-+ 0.00%
-+ 0.00%

GenFleet GFH375 wins China breakthrough status for KRAS G12D pancreatic cancer therapy

PUBT·05/18/2026 02:25:20
Listen to the news
GenFleet GFH375 wins China breakthrough status for KRAS G12D pancreatic cancer therapy
  • Apricot Capital portfolio company GenFleet Therapeutics secured a Breakthrough Therapy Designation in China for GFH375 as a monotherapy in KRAS G12D-mutant metastatic pancreatic cancer in patients who have received at least one prior systemic therapy.
  • The designation marks the first KRAS G12D inhibitor monotherapy included in China’s BTD list for pancreatic cancer.
  • GenFleet entered a Phase III registrational study for GFH375 monotherapy in 2025, described as the first registrational trial for an oral KRAS G12D inhibitor, run across about 40 sites in China.
  • Partner Verastem Oncology is developing the same asset outside China as VS-7375, which has US FDA Fast Track status for KRAS G12D-mutant pancreatic ductal adenocarcinoma across all lines of therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apricot Capital published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.